We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 03, 2020

Effect of Dapagliflozin on LV Hypertrophy in Type 2 Diabetes

European Heart Journal


Additional Info

Disclosure statements are available on the authors' profiles:

European Heart Journal
A Randomized Controlled Trial of Dapagliflozin on Left Ventricular Hypertrophy in People With Type Two Diabetes: The DAPA-LVH Trial
Eur Heart J 2020 Jun 24;[EPub Ahead of Print], AJM Brown, S Gandy, R McCrimmon, JG Houston, AD Struthers, CC Lang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading